To investigate the role of FADD in DD-receptor signaling, we introduced a plasmid encoding a fusion protein in which the amino-terminal death effector domain of FADD was replaced by GFP, into HeLa cells. The use of GFP allows easy and reliable detection of the fusion protein but also facilitates the generation of HeLa populations expressing high levels of GFP-∆FADD by rounds of fluorescence-activated cell sorting (FACS). Analysis by FACS of pools of pcDNA3.1-GFP-∆FADD transfectants revealed that 10-30% of these cells expressed the fusion protein, with expression levels varying over 3-4 orders of magnitude (data not shown). HeLa populations expressing high levels of GFP-∆FADD were obtained after three cycles of cell sorting (Figure 1a,b) . As shown in Figure 2a ,b, cell death mediated by TNFR60 and TRAIL-R/Apo2 was partially blocked in cells expressing intermediate levels of GFP-∆FADD, GFP-∆FADD(low), and was completely inhibited in cells expressing high levels of GFP-∆FADD, whereas control cells expressing GFP alone remained sensitive. As HeLa cells express only a limited amount of the Fas/Apo1 receptor, we introduced the GFP-∆FADD expression construct into HeLa cells that had already been transfected with the Fas/Apo1 receptor (HeLa-Fas) and were therefore susceptible to Fas/Apo1-mediated cell death. Fas/Apo1-mediated cell death was completely prevented in cells expressing GFP-∆FADD (Figure 2c) . Moreover, the sensitivity of all GFP-∆FADD transfectants against other apoptosis-inducing agents such as daunorubicin or ceramide was unaffected (data not shown), emphasizing the specificity of GFP-∆FADD action.
Results and discussion
To investigate the role of FADD in DD-receptor signaling, we introduced a plasmid encoding a fusion protein in which the amino-terminal death effector domain of FADD was replaced by GFP, into HeLa cells. The use of GFP allows easy and reliable detection of the fusion protein but also facilitates the generation of HeLa populations expressing high levels of GFP-∆FADD by rounds of fluorescence-activated cell sorting (FACS). Analysis by FACS of pools of pcDNA3.1-GFP-∆FADD transfectants revealed that 10-30% of these cells expressed the fusion protein, with expression levels varying over 3-4 orders of magnitude (data not shown). HeLa populations expressing high levels of GFP-∆FADD were obtained after three cycles of cell sorting (Figure 1a, b) . As shown in Figure 2a ,b, cell death mediated by TNFR60 and TRAIL-R/Apo2 was partially blocked in cells expressing intermediate levels of GFP-∆FADD, GFP-∆FADD(low), and was completely inhibited in cells expressing high levels of GFP-∆FADD, whereas control cells expressing GFP alone remained sensitive. As HeLa cells express only a limited amount of the Fas/Apo1 receptor, we introduced the GFP-∆FADD expression construct into HeLa cells that had already been transfected with the Fas/Apo1 receptor (HeLa-Fas) and were therefore susceptible to Fas/Apo1-mediated cell death. Fas/Apo1-mediated cell death was completely prevented in cells expressing GFP-∆FADD (Figure 2c) . Moreover, the sensitivity of all GFP-∆FADD transfectants against other apoptosis-inducing agents such as daunorubicin or ceramide was unaffected (data not shown), emphasizing the specificity of GFP-∆FADD action.
These results suggest that in HeLa cells FADD represents an essential part of the apoptotic pathways initiated by the TNFR60, TRAIL-R/Apo2 and Fas/Apo1 DD receptors, or that GFP-∆FADD interferes with other DD signaling proteins involved in these pathways. Transient expression studies in HeLa-S3 [9, 10, 21] and MCF7 [7, 9] cells, however, have suggested that the TRAIL/Apo2L couples to the caspase cascade via a FADD-independent pathway. FADD-independent pathways that connect DDreceptor signaling complexes with the caspase cascade have also been suggested by the cloning of the adaptor molecule RAIDD/CRADD [22, 23] , which comprises a carboxy-terminal DD that binds to the DD of the Fas-or TNFR-interacting protein, RIP, and an amino-terminal domain homologous to the predomain of caspase-2 [22, 23] . Such a FADD-independent pathway might not play a major role in HeLa cells, as RIP mRNA is barely detectable in these cells by RNAse protection assay (data not shown). Recent data have demonstrated the existence of at least two distinct DD receptors specific for TRAIL/Apo2L, termed DR4 (death receptor 4) [7] and DR5/TRICK2 (TRAIL receptor inducer of cell killing 2) [9] [10] [11] . Transient expression studies have suggested that FADD does not bind directly to these receptors [9, 10] . Similarly, we were unable to detect GFP-∆FADD in TRAIL/Apo2L immunoprecipitates (data not shown). In accordance with these data, expression of ∆FADD had no effect or only minor effects on cell death induced by overexpression of DR4 [7] and DR5 [9, 10] . Results of these transient assays are not, however, directly comparable to the data obtained here using stable GFP-∆FADD transfectants, as expression following transient transfection is extremely heterogeneous (data not shown).
Hsu et al. [12] have recently shown that the TNFR60-induced pathways leading to apoptosis and activation of NF-κB bifurcate at the level of TRADD. Whereas the amino terminus of TRADD mediates binding to TRAF2 (TNFR-associated factor) [13] , which in turn activates NF-κB by stimulating the phosphorylation of IκBα mediated by NIK (NF-κB-inducing kinase) [24] , the carboxyterminal DD of TRADD mediates FADD binding and subsequent activation of the caspase cascade [13] . As thereby expected, GFP-∆FADD expression had no effect on NF-κB or JNK activation by TNF (Figure 3a,b) . We have recently shown that TNF upregulates cIAP2 (inhibitor of apoptosis) and TRAF1 mRNA in HeLa cells (T.W. and H.W., unpublished observations). As shown in Figure 3c , there is no difference in the TNF-mediated induction of these genes in the HeLa-GFP-∆FADD cells, compared to the HeLa-GFP cells. This result is consistent with a bifurcation of the pathways that induce apoptosis (caspase cascade) and gene activation (via NF-κB, JNK) at the level of TRADD. In contrast with TNFR60 signaling, engagement of Fas/Apo1 results in the activation of JNK but not NF-κB (data not shown). The activation of JNK by Fas/Apo1 was also unaffected in HeLa-Fas-GFP-∆FADD transfectants (Figure 3d ). This finding is in good accordance with experiments demonstrating that Daxx, a recently identified Fas/Apo1-binding protein, activates JNK independently from FADD and potentiates the apoptotic pathway initiated by Fas/Apo1 [25] . Because Fas/Apo1-mediated activation of JNK is significantly increased in HeLa-Fas-GFP-∆FADD cells compared with control cells, cross-talk might occur between the FADD-dependent and Daxx-dependent signaling pathways initiated by Fas/Apo1.
Materials and methods

Generation of pcDNA3.1-GFP-∆FADD
Full-length EGFP, a red-shifted variant of wild-type GFP, was amplified by PCR from pEGFP-N1 (Clontech) using oligonucleotides designed to amplify the complete coding region and add BglII and HindIII sites. These sites were used for subsequent cloning into pcDNA3.1∆FADD. The ∆FADD fusion protein contains amino acids 80-208 of FADD with the death effector domain of FADD being replaced by EGFP.
Cells, DNA transfection, cell sorting and cytotoxicity assay
HeLa cell lines were grown under standard conditions. Lipid-vesiclemediated transfections were carried out using Pfx-2 (Invitrogen) according to the manufacturer's instructions. Transfected cells were selected in culture medium containing 600 µg/ml G418 (Gibco BRL). At 20 days post transfection, individual drug-resistant colonies were pooled, expanded and enriched for highly expressing cells by three cycles of cell sorting using a FACStarplus (Becton and Dickinsion). Cytokine-induced apoptosis was measured by determination of viability using crystal-violet staining essentially as described [26] .
EMSA analysis of NF-κB and JNK activation
Electrophoretic mobility shift assays were performed as previously described [26] . Assays of JNK activity were performed after immunoprecipitation of JNK1 using a rabbit antiserum (Santa Cruz Biotechnology). GST-Jun was used as the substrate in an in vitro kinase assay essentially as described [27] .
RNase protection assays
Cells (5-10 × 10 6 ) were treated with the reagents indicated in Figure 3 and RNA was subsequently isolated with the RNeasy RNA purification kit (Qiagen) according to the manufacturer's recommendations. The RNA samples were analyzed for the presence of transcripts of xIAP, TRAF1, TRAF2, CART, NAIP, cIAP2, cIAP1, TRPM2 and TRAF3 with the hApo-5 Multi-Probe template set (PharMingen). L32 and GAPDH were included as internal controls. RNase protection assays were performed with the RiboQuant Multi-Probe RNase Protection Assay System (PharMingen) according to the manufacturer's recommendations. Protected transcripts were separated by denaturing polyacrylamide gels and quantified using a phosphorimager.
